|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: HIV - Enter the New Generation Inhibitors
Datamonitor, April 2004, Pages: 275
Introduction
Currently there is a range of marketed antiretrovirals for the treatment of HIV, the majority of which were launched between the years 1990 to 2000. These are slowly being replaced by products with lower pill burden, higher potency and less incidence of adverse side effects. Those candidates with efficacy against resistant strains or novel having mechanisms of action now dominate the pipeline.
Scope
Up to date review and comment of HIV epidemiology, HAART therapy, key drug classes and unmet needs analysis within HIV clinical trial design
Key HIV pipeline metrics including candidates by phase, class and company participation; discussion of major and new entrant strategies
Full commercial reappraisal of HIV market with candidate and product global forecasts to 2012; discussion of new combinations and patent expiries
Expert comment on second generation NRTIs, NNRTIs and PIs. Critical analysis on potential of CCR5 antagonists and CD4 inhibitors
Report Highlights
Datamonitor’s recent survey of 32 HIV pipeline products (Phase I to Phase III) suggests that by 2012, global product sales could amount to just under $12 billion, approximately double the value recorded for 2003 ($5.76 billion).
In the medium term (2003-2008), 10 product launches are predicted. For the first time, four original NRTI antiretroviral products will also face patent expiry namely, Retrovir, Videx, Hivid and Zerit.
Within the HIV pipeline, around a third of candidates are classified as entry inhibitors/others. Datamonitor predicts that in 2012, 16% of total sales revenue could be derived from these novel compounds. Presently these appear safe and orally available, but more importantly, are being developed by major players.
Reasons to Purchase
Access the latest market information and forecasts for current HIV pipeline candidates
Benchmark internal forecasts, and review Datamonitor’s objective appraisals of candidate profiles
Understand potential HIV company and drug class contribution to revenue growth to 2012
|
|
|
|
